William Blair Cuts Earnings Estimates for Beam Therapeutics

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair dropped their Q2 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, May 6th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.01) for the quarter, down from their prior forecast of ($0.94). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. William Blair also issued estimates for Beam Therapeutics' Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($4.09) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.91) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.13). The firm had revenue of $7.47 million during the quarter, compared to analysts' expectations of $14.69 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.21) EPS.

A number of other brokerages also recently issued reports on BEAM. Scotiabank raised Beam Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $40.00 target price for the company in a research note on Monday, March 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and issued a $57.00 target price on shares of Beam Therapeutics in a research note on Monday, March 10th. Royal Bank of Canada raised their price objective on Beam Therapeutics from $24.00 to $26.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 26th. Finally, Guggenheim cut their price objective on Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Beam Therapeutics currently has an average rating of "Buy" and an average price target of $48.75.

Beam Therapeutics Trading Up 4.8%

BEAM stock traded up $0.83 during midday trading on Friday, reaching $18.24. The stock had a trading volume of 2,231,538 shares, compared to its average volume of 1,435,975. The company's fifty day simple moving average is $20.07 and its 200 day simple moving average is $24.36. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -10.36 and a beta of 2.35. Beam Therapeutics has a 52-week low of $13.53 and a 52-week high of $35.25.

Insider Buying and Selling

In related news, CEO John M. Evans sold 30,663 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total transaction of $562,666.05. Following the completion of the sale, the chief executive officer now owns 986,249 shares in the company, valued at $18,097,669.15. The trade was a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Giuseppe Ciaramella sold 7,434 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $136,413.90. Following the completion of the sale, the president now owns 190,216 shares of the company's stock, valued at approximately $3,490,463.60. This represents a 3.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,771 shares of company stock worth $803,198 over the last 90 days. 4.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Beam Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BEAM. Horizon Kinetics Asset Management LLC lifted its stake in shares of Beam Therapeutics by 4.4% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 9,597 shares of the company's stock valued at $238,000 after purchasing an additional 403 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Beam Therapeutics by 6.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,999 shares of the company's stock valued at $198,000 after buying an additional 496 shares during the period. Amalgamated Bank raised its holdings in shares of Beam Therapeutics by 20.4% during the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company's stock valued at $62,000 after buying an additional 534 shares during the period. Avanza Fonder AB raised its holdings in shares of Beam Therapeutics by 1.6% during the 1st quarter. Avanza Fonder AB now owns 51,077 shares of the company's stock valued at $944,000 after buying an additional 792 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Beam Therapeutics by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,492 shares of the company's stock valued at $205,000 after buying an additional 879 shares during the period. Hedge funds and other institutional investors own 99.68% of the company's stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.